Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM830EN)

Drug Name
NEO-201 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM830EN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Biliary glycoprotein 1 (CEACAM1) TTA9CK4 CEAM1_HUMAN Inhibitor [2]
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 5.812 11.49 6.112 6.957
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 6.68E-91 0.29 1.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03476681) QUILT-3.017: Study of NEO-201 in Solid Tumors. U.S. National Institutes of Health.
2 The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198.